ArteraAI

We are excited to be presenting a slate of important data presentations at @SABCS in a few weeks, showcasing the validation of our #MMAI model in early-stage #breastcancer. Across multiple Phase III trials and in over 12,000 patients across the world, our model demonstrated prognostic utility in order to help clinicians and patients personalize care. In addition, through our work with the NSABP B-20 trial, we demonstrated the ability to predict chemotherapy benefit in postmenopausal patients with breast cancer. All of this based on a few simple inputs - the patient's clinical variables and histopathology images of the surgical specimen. Read more here: https://heyor.ca/zCrytY

#ArteraAI Product Update: On November 3rd, 2025, we released a design update for our Prostate Test Report to improve its clinical interpretability. The changes focused on updated charts and graphs, with no impact to the underlying model or results. These changes are applicable only to the reports for NCCN High- and Very High-Risk patients. View a preview of some of these changes in the image below and see the full update here: https://lnkd.in/g4S3XE6B

The ArteraAI Prostate is the first FDA-authorized digital pathology software powered by AI for predicting long-term outcomes in non-metastatic prostate cancer. This article highlights how our AI platform is helping address one of the toughest challenges in prostate cancer care: knowing who needs treatment, and who doesn’t. ✔️ Faster results at the time of diagnosis ✔️ Personalized insights to avoid over-treatment or under-treatment ✔️ Clinical and financial impact for patients and the healthcare system A huge thank you to Dr. Adam Cole and MSN for spotlighting how this innovation can support better outcomes, smarter decisions, and more peace of mind. Read the full article: https://lnkd.in/gY579FrS #ArteraAI #ProstateCancer #AIinHealthcare #DigitalPathology #PrecisionMedicine #HealthEquity

“That waiting process, from a patient perspective, is often the hardest part.” — Dr. Adam Cole via @CUREToday Thank you, Dr. Cole, for highlighting how Artera’s platform can help reduce patient anxiety by delivering faster, clinically meaningful results. By providing actionable insights in just 1–2 days, we’re helping patients and their care teams make confident, timely treatment decisions, because waiting shouldn’t be part of the burden. Read the article: https://heyor.ca/RLvGKn #ArteraAI #ProstateCancer #PrecisionMedicine

Get the latest jobs and industry news